The analysis included 826,000 people, with researchers from the University of Cambridge looking at 33 studies on three ...

Not everyone living with type 2 diabetes or obesity needs a GLP-1 receptor agonist or is a candidate for one. Your doctor can discuss the benefits and contraindications of this therapy and why it ...